Oxford Textbook of Cancer in Children

The outcome for children with cancer has shown enormous improvement since the first edition of this book was published in 1975. In economically privileged countries, overall survival rates have now reached 80% at five years from diagnosis, and most of these young people will become long term survivors. The Oxford Textbook of Cancer in Children offers state-of-the-art descriptions of the approach needed for the optimal management of children with cancer, and guidance on current treatments available due to the advances made over the past decade.

This seventh edition has been thoroughly revised and updated, including brand new chapters on cancer immunotherapy in children, and cancer in adolescents and young adults, plus expanded treatment of tumours of the brain and central nervous system. The book primarily provides clear and up-to-date clinical guidance for use in treatment settings whilst offering a useful background to the biology of individual tumour types and the history of the development of specific treatments.

With an international and multi-disciplined authorship comprising of paediatric oncologists, surgeons, radiotherapists, imaging specialists, psychologists, nurses, and many others, the text illustrates how the paediatric oncology community works globally and collaboratively in order to drive forward new therapies, build our knowledge of these diseases, and achieve the common aim of curing childhood cancer. In this new edition, Professors Biondi and Caron have been joined by Professor François Doz, who has a distinguished international reputation, particularly in the treatment of childhood brain tumours and retinoblastoma, as well as early drug development. They have also been joined by Professor Tom Boterberg, a world renowned radio-oncologist for children with cancer.

This book will be of value to paediatric oncologists, trainee paediatric oncologists, paediatric haematologists, and other professionals working in paediatric oncology: nurses, AHPs, surgeons, and clinical oncologists.

Andrea Biondi M.D., took the degree in Medicine in 1979 at the University of Milano, Italy and in 1982 and 1994 the Specialization in Pediatrics and Haematology respectively. In 1982-84 he was Research Associate in Pathology at the Dana Farber Cancer Institute-Harvard Medical School, Boston, USA. In 1986-1987 he was Research Associate in Medicine at the Ontario Cancer Institute, Toronto, Canada. Since November 2009, he has been the Director of the Department and the School of Paediatrics, University of Milano-Bicocca, San Gerardo Hospital, Monza (MI), Italy. He is head of the M.Tettamanti Research Centre and of S. Verri Cellular and Gene Therapy Laboratory, San Gerardo Hospital, Monza (MI), Italy. Since 2007 he has been Coordinator of the Ph.D. Program in Translational and Molecular Medicine at University of Milano-Bicocca, Milan, Italy. From 2004-08 he was President of SIOP Europe. His clinical and research interests relate to childhood leukaemia and to cell and gene therapy.

Tom Boterberg graduated as an MD in 1994 at Ghent University. After one year of residency in radiation oncology, he worked for 4 years at the Laboratory of Experimental Cancer Research on the biology of the invasive and metastatic behaviour of breast cancer cells. He obtained his PhD in 2000. Afterwards he continued his training in radiation oncology and in 2001 he obtained his Board Certificate in Radiation Oncology. Since 2001 he works as a staff member at the Department of Radiation Oncology at Ghent University Hospital. He is especially interested in paediatric radiotherapy. He is actively involved in the radiotherapy committees of SIOPEN (neuroblastoma) and EpSSG (rhabdomyosarcoma). He is board member of SIOPE and chairs the QUARTET project on quality assurance in paediatric radiotherapy. He is author or co-author of over 100 articles in peer-reviewed journals. His other interests are haematology, neuro-oncology, intra-operative brachytherapy and radioprotection.

Hubert Caron graduated in medicine in 1985 from the Medical School, University of Amsterdam, trained in paediatrics and in paediatric oncology in Emma Children's Hospital, AMC Amsterdam and was appointed professor in paediatric oncology in 2001. He received his PhD (cum laude) in 1995 on the subject "Chromosome 1P in Neuroblastoma: suppressors and prognosis". His main research interests are tumour biology, rational targeted drug design, early new drug trials, systematic reviews of effectiveness of interventions in paediatric oncology and late effects of treatment. Since 2014 he also holds a position as medical director at Roche, where he is responsible for the global clinical development of the oncology portfolio of Roche for children with cancer.

François Doz is professor of Paediatrics at the University Paris Descartes and paediatric oncologist at Institut Curie, Paris. He got his MD, paediatric specialty and master in pharmacology in Paris. He then spent two years as a research fellow in the Brain Tumour Research Center, University of California, San Francisco. His main research interests are Paediatric Neuro-oncology, Retinoblastoma, Early Drug Development and Ethics of Clinical Research. He is past- member (2011-2013, 2017) and past-chair (2014-2016) of the SIOP scientific committee, past-chair of the scientific committee of the SFCE (French paediatric cancer society) (2007-2011), member of the SIOPE Board, past- chair of the SIOP-Europe Brain Tumour Group (2006-2010) and of its Medulloblastoma/PNET working group (2013-2016), member of the clinical trial committee and of the executive committee of the ITCC consortium (Innovative Treatment for Children with Cancer) and current co-chair of the European Retinoblastoma Group.